Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Lomitapide Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi Global Rare Receives Positive CHMP Opinion for LOJUXTA
    Chiesi Global Rare Receives Positive CHMP Opinion for LOJUXTA

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264586/0/en/Chiesi-Global-Rare-Diseases-Receives-Positive-CHMP-Opinion-for-LOJUXTA-lomitapide-Capsules-for-Paediatric-Use-in-Homozygous-Familial-Hypercholesterolemia-HoFH.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Chiesi Global Rare Diseases Gets FDA Nod For JUXTAPID
    Chiesi Global Rare Diseases Gets FDA Nod For JUXTAPID

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248283/0/en/Chiesi-Global-Rare-Diseases-Announces-FDA-Approval-of-JUXTAPID-lomitapide-Capsules-for-Pediatric-Use-in-Homozygous-Familial-Hypercholesterolemia-HoFH.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide
    Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide

    05 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/01/05/2583508/0/en/Amryt-Announces-Positive-Top-Line-Results-from-Phase-3-Pediatric-Trial-of-Lomitapide-in-HoFH.html

    GLOBENEWSWIRE
    05 Jan 2023
    Share Share
    Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma
    Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma

    25 Sep 2019

    // Amber Tong ENDPTS

    https://endpts.com/coming-out-of-chapter-11-aegerion-jumps-into-welcome-arms-of-irish-pharma-with-big-plans-fresh-60m-for-its-drugs/

    Amber Tong ENDPTS
    25 Sep 2019
    Share Share
    Regeneron preps for 2020 filing for new cholesterol drug after trial success
    Regeneron preps for 2020 filing for new cholesterol drug after trial success

    18 Aug 2019

    // PHARMAPHORUM

    https://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/

    PHARMAPHORUM
    18 Aug 2019
    Share Share
    Armed stellar if niche PhIII, Regeneron steers 'breakthrough' cholesterol drug
    Armed stellar if niche PhIII, Regeneron steers 'breakthrough' cholesterol drug

    14 Aug 2019

    // Amber Tong ENDPTS

    https://endpts.com/armed-with-stellar-if-niche-phiii-data-regeneron-steers-breakthrough-cholesterol-drug-to-post-pcsk9-waters/

    Amber Tong ENDPTS
    14 Aug 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.